MRFR Year End Sale
Obesity Treatment Market Research Report – Forecast to 2030

Obesity Treatment Market Research Report, by Type (Inactivity, Obesity gluten, Obesity), Diagnosis (Blood Tests, Physical Examination), Treatment (Medication, Surgery, Lifestyle Changes), End-Users (Hospitals, Clinics) - Forecast Till 2030

ID: MRFR/Pharma/4416-HCR | December 2022 | Region: Global | 100 Pages         

Obesity Treatment Market

Obesity Treatment Market is expected to register a CAGR of 16.7 % and was valued at USD 31.7 Billion.

Segmentation

By Type Inactivity Obesity gluten Obesity
Diagnosis Blood Tests Physical Examination
Treatment Medication Surgery Lifestyle Changes
End-Users Hospitals Clinics

Key Players

  • VIVUS
  • Inc. (U.S.)
  • Arena Pharmaceuticals
  • Inc. (U.S.)
  • F. Hoffmann-La Roche
  • Ltd. (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Orexigen Therapeutics
  • Inc. (U.S.)
  • Allergan (Republic of Ireland)
  • Cousin Biotech (France)
  • EnteroMedics
  • Inc. (U.S.)
  • Johnson & Johnson Services
  • Inc. (U.S.)
  • Medtronic (U.S.)
  • USGI Medical
  • Inc. (U.S.)
  • Mediflex Surgical Products (U.S.)
  • Covidien plc (Republic of Ireland)
  • Olympus Corporation (Japan)
  • and others.

Drivers

  • Increasing demand for minimally invasive surgeries
  • Favorable reimbursement policies.
Speak to Analyst Request a Free Sample

Obesity Treatment Market Overview:


The obesity treatment market is expected to rise at CAGR of 16.7% to reach USD 31.7 billion during the forecast period 2022-2030. In recent years, industrialized countries have seen an alarming rise in the prevalence of health issues, including diabetes, cardiovascular illnesses, and cancer. In North America and Western Europe, changing eating patterns, sedentary lifestyles, and high disposable money make people more likely to suffer health issues like diabetes and cancer. Therefore, the acceptance of weight reduction and weight management solutions has been facilitated by the growth in the prevalence of health conditions. Additionally, growing fitness awareness in China and India due to improved lifestyles and altered eating patterns is anticipated to present profitable business prospects to companies in the worldwide weight loss and weight control diet market.


For industry participants, the Asia-Pacific region's weight loss and weight control diet market have significant development potential. This may be linked to an increase in disposable income and adopting western lifestyles, which are the main drivers of market expansion. Additionally, this area may present the opportunity for market participants to introduce premium, calorie-efficient goods. Manufacturers are concentrating on growing their company in this area to boost their consumer base and broaden their geographic reach. Additionally, due to the high incidence of obesity in this region, nations in Latin America like Brazil are projected to present lucrative weight loss and weight management diet market prospects throughout the projection period.


Engaged parties in the weight loss and weight management diet business review their sourcing plans, narrow the selection of products, and evaluate the adaptability and durability of new supply chains to access new distribution channels. Additionally, e-commerce distribution networks are being simplified and improved to fully use the online sales channel's potential.


COVID 19 Analysis:


The pandemic hit has affected almost every industrial and commercial unit across the globe. Some medical branches have also experienced a significant decline due to the COVID 19. The restrictions in the movement have restricted people from visiting hospitals for regular health checkups and conditions like obesity treatments. There was a significant decline in obesity drug management and subscriptions in recent years. Additionally, the surgeries related to obesity issues have been postponed to attend to the ongoing crisis.


However, the advent of technology consultants and sedentary lifestyle, work from home trends has propelled the overall growth of the Obesity treatment market demand.


Obesity Treatment Market Dynamics:


Market drivers:


The work-from-home trends and lack of physical exercise, unhealthy diet, and routines have increased the rate of obesity in recent times. Improper food habits and trends like ordering food online and increasing packed food and ready-to-eat food packages trends have created a huge impact over a wide scale of the population. The Institute of Health Metrics and Evaluation has claimed that over 30% of the world population is categorized as obese or overweight. Such factors and reports have propelled the demand for the Obesity Treatment industry.


Rising weight management programs, applications, and websites that guide and monitor the regular activity of the individual have promoted the awareness among the population about the concerns associated with overweight. Surging electronic and wearable devices that constantly monitor the health parameters have also created a huge impact on the growth of the Obesity Treatment industry in recent years.


Market opportunities:


The advancements in the surgeries and devices utilized in surgeries related to obesity treatment have bolstered the growth of the Obesity treatment industry in recent years. The U.S National Institute of Health has recommended Bariatric surgeries for obese people whose body mass index is above 40. With the positive recommendations of medical associations and initiatives, the obesity treatment market is expected to have a steady growth in the forecast period.


The analysis done on bariatric surgery has proven that the life expectancy of the patients who have undergone bariatric surgery has been increased by 9.3 years. The reduction in cardiovascular events and diabetes-related complications after undergoing bariatric surgery is considered the primary driving factor for the Obesity Treatment industry. 


Market restraints:


The medications such as Lorcaserin and Phentermine-topiramate are highly associated with factors causing heart valve problems. The American Association has removed Lorcaserin from the market in the year 2020 since the medication is associated with cancer-causing agents. Orlistat is highly associated with the factors causing gastrointestinal side effects. These reports have adversely impacted the Obesity Treatment market growth in recent years.


After acquiring the obesity treatment, there are about 17% chances for complications and 7% chances for reoperation. Such factors are considered as the primary restraints of the growth of the Obesity market growth.


Market challenges:


The cost incurred for the Obesity treatment ranges between USD 1239 to USD 2582 per person per year, excluding the miscellaneous expenses associated with the treatment. Moreover, developing countries don’t provide reimbursement facilities for these procedures. They are considered as the major challenges for the growth of the Obesity Treatment market.


The risks of getting infections and allergic to the medications and side effects associated with the treatment are also considered as challenges for the growth of the Obesity Treatment market. After undergoing costlier treatments, gaining weight after surgery is significantly impacting the growth of the Obesity Treatment market.


Cumulative growth analysis:


Over other significant causes, Malnutrition at the early stages of life is playing a crucial role in gaining weight. Since the major endocrine changes that occur during the period of malnutrition tend to accumulate more fat once it becomes available. On the other hand, changing trends in lifestyle, urbanization is considered as the primary reasons for the Obesity treatment market. 


The restrictions in movements due to the pandemic have further bolstered the overall growth of the Obesity treatment market in several countries.


Dieting is a lifestyle change and regular physical exercise has a huge impact on controlling body weight. Continuous energy restriction and hypo-caloric diets are recommended by professionals to attain weight loss goals. Smoking and decreased intake of sweet or aerated drinks are highly associated with obesity. The surging awareness of the condition, even in developing countries has a significant impact on the overall growth of the Obesity Treatment industry.


Value chain analysis:


The gastric bypass surgery which bypasses the food, and reduces the size of the stomach thereby showcases significant results in acquiring weight loss. However, the huge risk of not absorbing essential nutrients and minerals is accompanied by the procedure. Recently, medical professionals are more likely advising bariatric surgery for treating obesity.


The increasing prevalence of conditions like type-2 diabetes, high blood pressure, cardiovascular problems that are highly associated with obesity are the primary drivers of the Obesity Treatment market growth. On the other hand, minimally invasive endoscopic procedures are also driving market growth in recent years. 


Segment overview:


Based on Surgery Type:



  • Biliopancreatic diversion with Duodenal Switch (BPD/DS)

  • Adjusting Gastric Banding

  • Roux-en-Y Gastric Bypass

  • Sleeve gastrectomy

  • Endoscopic Procedures


Based on Drug Type:



  • Appetite suppressants

  • Combination drugs

  • Malabsorption

  • Satiety drugs


Based on End-user:



  • Clinics

  • Hospitals

  • Beauty institutions

  • Others


Regional analysis:


Urbanization is considered as one of the primary causes of Obesity. Hence North America is accounting for the largest market share with over 53% in recent times. Additionally, the higher R&D developments, minimally invasive procedures, and effective weight management solutions in the region are considered as the primary factors that are bolstering the Obesity Treatment market growth.


Asia-pacific is accounting for over 18% of CAGR in recent years owing to the increasing awareness about the health issues associated with obesity and social media exposure. The advancing medical facilities and infrastructure in the region are also the primary reasons for the growth of the Obesity Treatment Market in these regions.


Competitive Landscape:



  • VIVUS, Inc. (U.S.)

  • Arena Pharmaceuticals, Inc. (U.S.)

  • F. Hoffmann-La Roche, Ltd. (Switzerland)

  • Novo Nordisk A/S (Denmark)

  • Orexigen Therapeutics, Inc. (U.S.)

  • Allergan (Republic of Ireland)

  • Cousin Biotech (France)

  • EnteroMedics, Inc. (U.S.)

  • Johnson & Johnson Services, Inc. (U.S.)

  • Medtronic (U.S.)

  • USGI Medical, Inc. (U.S.)

  • Mediflex Surgical Products (U.S.)

  • Covidien plc (Republic of Ireland)

  • Olympus Corporation (Japan)

  • Takeda Pharmaceuticals Company Limited

  • Eisai Co. Ltd.

  • Novo Nordisk A/S

  • Zafgen

  • Rhythm Pharmaceuticals

  • Zydus Cadila

  • Norgine B.V.

  • Vivus Therapeutics

  • Arena Pharmaceuticals Inc.

  • Orexigen Therapeutics Inc


Recent Developments:


In industrial facilities, automation techniques are now being used to minimize staff density. Focus has switched from the epidemic toward autonomous material mobility, predictive maintenance utilizing IoT & AI, and upgrading automation in labor-intensive operations like assembly lines.


Report Overview:


This report has covered:



  • Market overview

  • COVID 19 Analysis

  • Market dynamics

  • Cumulative growth analysis

  • Value chain analysis

  • Segment overview

  • Regional analysis

  • Competitive landscape

  • Recent developments



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 31.7 billion
  CAGR   16.7%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-user.
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.
  Key Market Opportunities

  • Growing obese population
  • Increasing acceptance of bariatric surgeries
  •   Key Market Drivers

  • Increasing demand for minimally invasive surgeries
  • Rising awareness
  • Favorable reimbursement policies


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The Obesity Treatment Market is expected to exhibit a strong 16.7% CAGR over the forecast period till 2030

    VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.

    The growing prevalence of obesity is the major driver for the market.

    North America is the leading regional market for obesity treatment.